Please enter your date of birth to confirm you are an adult user of nicotine or tobacco products.

CONFIRM

Sorry!
This website is intended only for users of nicotine or tobacco products who are over 18.

We Care

This website is about selling new tobacco products and contains information about them. Entrance is only permitted to persons over 18 years of age who are also users of nicotine products. We need your age to make sure that you are an adult in Greece. Our nicotine and tobacco products are not an alternative to quitting and are not designed as cessation aids. They are not risk free. They contain nicotine, which is addictive. Only for use by adults. Please visit the Important Information page of this website for further risk information.

A man's hands opening an IQOS ILUMA device.

The science and the research behind IQOS.

Our scientific assessment journey.

A jade green IQOS ILUMA device and holder.

IQOS satisfaction.

Our clinical study participants who switched to IQOS also report that IQOS provides comparable levels of satisfaction as cigarettes. This supports our view that IQOS has the potential to be an acceptable alternative for adult smokers who would otherwise continue to smoke. Based on all the scientific evidence, we are confident that switching completely to IQOS is less harmful than continuing to smoke cigarettes.

However, and this is important: IQOS is not risk-free. The absolute best choice remains to quit tobacco and nicotine use altogether. IQOS is not an alternative to cessation. It delivers nicotine, which is addictive.

Man holds an IQOS ILUMA azure blue device.
An obsidian black IQOS ILUMA device and holder.

Long-term studies.

Once IQOS is available in the market, the research moves from being conducted in a pre-market setting to a real-world post-market setting. There, we look at how the product is being used and by whom in order to complement our pre-market findings and to do our best to identify and prevent use or uptake by unintended audiences. After years of commercialization in many countries, the available data confirms our pre-market observations, in particular in terms of IQOS’ appeal to adult smokers and the relative lack of interest in former and never smokers.

We also monitor reports of health effects now that the product is used by millions of adult users. Long-term studies will eventually help us to evaluate the potential disease–specific risk reduction of IQOS. Gathering data to answer this question takes time, but it’s the right choice. So far, all the data we’ve seen points in the right direction.

Close up of a brilliant gold IQOS device.